Indaptus Therapeutics, Inc.(INDP), Monday announced the initiation of a new expansion arm in its Phase 1b/2 clinical trial to evaluate the combination of Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, for the treatment of advanced solid tumors.
The expansion arm will assess the safety, optimal dosing, and early anti-tumor activity of Decoy20 in combination with tislelizumab.
Initial participants will receive a week of Decoy20 monotherapy before transitioning to the combination treatment, with early patients enrolled sequentially to monitor safety.
Following a review by the trial's Safety Review Committee, enrollment will open to all eligible participants. Patients will receive the combination treatment for up to one year or until disease progression, unacceptable toxicity, or withdrawal from the study.
Indaptus believes Decoy20's ability to activate immune system pathways may enhance the effectiveness of PD-1 inhibitors, addressing the unmet need for patients who do not respond to or maintain long-term benefits from checkpoint inhibitors alone.
This combination trial represents a significant step for Indaptus as it aims to expand its Decoy platform and explore its potential in improving cancer treatments.
Currently, INDP is trading at $0.92 up by 16.1 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.